<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776841</url>
  </required_header>
  <id_info>
    <org_study_id>PROTOCOL No: TRC 037/10072</org_study_id>
    <nct_id>NCT00776841</nct_id>
  </id_info>
  <brief_title>A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galmed Medical Reserch</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galmed Medical Reserch</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose&#xD;
      Study of Aramchol in Healthy Male Volunteers.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        1. To assess and characterize the safety and tolerability of Aramchol in 16 healthy male&#xD;
           subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight,&#xD;
           mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses&#xD;
           (Part B)&#xD;
&#xD;
        2. To assess the pharmacokinetics of Aramchol at the administered doses&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number of Subjects:&#xD;
&#xD;
      Total: A total of 46 healthy subjects will be enrolled. Part A: Sixteen (16) subjects will&#xD;
      participate in four, 8-person dosing periods. Each cohort will be alternately dosed twice.&#xD;
&#xD;
      Part B: Thirty (30) subjects will be enrolled in two, 15-person dose-ascending cohorts.&#xD;
&#xD;
      Main Inclusion Criteria:&#xD;
&#xD;
      Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written&#xD;
      informed consent Part B: Mildly overweight (25&lt;BMI&lt;33), with fasting cholesterol levels of&#xD;
      200-300 mg/% or LDL 100-180 mg/% and triglycerides &lt; 200 mg/%, otherwise healthy male&#xD;
      volunteers aged 18-50 (inclusive) years, who have provided written informed consent&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and tolerability and Pharmacokinetics of Aramchol at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, subjects receiving multiple doses (Part B)</measure>
    <time_frame>day 1 to 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess and characterize the drug effect on lipid profile and functional pharmacodynamics following single and multiple dose administrations.</measure>
    <time_frame>day 1 to 6</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 900 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1 repeated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 30 mg for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 repeated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose high for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aramchol</intervention_name>
    <description>1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 1 repeated</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 2 repeated</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)</other_name>
    <other_name>fatty-acid bile-acid conjugate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aramchol</intervention_name>
    <description>Oral Aramchol at dose 30 mg to 900 mg</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aramchol</intervention_name>
    <description>Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 1 repeated</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 2 repeated</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written&#xD;
             informed consent&#xD;
&#xD;
          -  Part B: Mildly overweight (25&lt;BMI &lt;33), with fasting cholesterol levels of 200-300&#xD;
             mg/% or LDL 100-180 mg/% and triglycerides &lt; 200 mg/%, otherwise healthy male&#xD;
             volunteers aged 18-50 (inclusive) years, who have provided written informed consent&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          -  History of significant neurological (including history of seizures or EEG&#xD;
             abnormalities), renal, cardiovascular (including known structural cardiac&#xD;
             abnormalities or hypertension), respiratory (asthma), endocrinological,&#xD;
             gastrointestinal, hematopoietic disease, neoplasm, psychological (marked anxiety,&#xD;
             tension or agitation) or any other clinically significant medical disorder, which in&#xD;
             the investigator's judgment contraindicate administration of the study medications.&#xD;
&#xD;
          -  History of drug or alcohol abuse.&#xD;
&#xD;
          -  Known allergy to any drug. Known allergy to any drug.&#xD;
&#xD;
          -  Clinically significant abnormalities found in the screening physical exam.&#xD;
&#xD;
          -  Significant abnormalities in clinical laboratory parameters (hematology, biochemistry,&#xD;
             urinalysis) determined within 40 days of the start of the study and on Day (-1) before&#xD;
             first dosing session. Parameters to be measured are those shown in Appendix 2.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Atsmon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>TASMC CLINICAL RESEARCH CENTER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tasmc Clinical Research Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>October 19, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Itzchak Angel, Vice President, Research &amp; Development</name_title>
    <organization>Galmed Medical Research</organization>
  </responsible_party>
  <keyword>Phase-I</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Obesity</keyword>
  <keyword>fatty liver</keyword>
  <keyword>Part A: Healthy male volunteers Part B: Mildly overweight, otherwise healthy hypercholesterolemic male volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholic Acids</mesh_term>
    <mesh_term>Bile Acids and Salts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

